Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.6K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.2K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.2K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

959
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
959
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

2.3K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the National Early Warning Score (NEWS) in triage: A machine learning perspective.

International emergency nursing·2025
Same author

Chat-GPT in triage: Still far from surpassing human expertise - An observational study.

The American journal of emergency medicine·2025
Same author

Artificial intelligence (ChatGPT 4.0) vs. Human expertise for epileptic seizure and epilepsy diagnosis and classification in Adults: An exploratory study.

Epilepsy & behavior : E&B·2025
Same author

The Face Reader: Jean-Martin Charcot (1825-1893) and Facial Expressions in Progressive Supranuclear Palsy.

Movement disorders clinical practice·2025
Same author

Reproducibility of the Manchester Triage System: a multicentre vignette study.

Emergency medicine journal : EMJ·2025
Same author

From testicles to brain: Understanding Dante's dream through medieval medicine.

Journal of the history of the neurosciences·2025

Related Experiment Video

Updated: Mar 31, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.7K

Stiripentol for focal refractory epilepsy.

Francesco Brigo1, Monica Storti, Stanley C Igwe

  • 1Department of Neurological and Movement Sciences, University of Verona, P.le L.A. Scuro, 10, Verona, Verona, Italy, 37134.

The Cochrane Database of Systematic Reviews
|October 22, 2015
PubMed
Summary

This review found no clear evidence that stiripentol (an antiepileptic drug) effectively reduces seizures in focal refractory epilepsy. Stiripentol was associated with a higher risk of adverse effects, indicating a need for more research.

More Related Videos

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.9K
Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
09:06

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

10.2K

Related Experiment Videos

Last Updated: Mar 31, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.7K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.9K
Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
09:06

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

10.2K

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Trials

Background:

  • Epilepsy affects millions globally, with nearly 30% experiencing uncontrolled seizures despite current treatments.
  • Stiripentol, an antiepileptic drug (AED), was approved in 2007 for Dravet syndrome but its efficacy in other epilepsy forms is under investigation.
  • This review is an update of a 2014 Cochrane review examining stiripentol's role in refractory epilepsy.

Purpose of the Study:

  • To assess the effectiveness of stiripentol as an add-on therapy for focal refractory epilepsy.
  • To evaluate the tolerability and safety profile of stiripentol in this patient population.
  • To identify any new randomized controlled trials (RCTs) published since the last review.

Main Methods:

  • Searched major databases (Cochrane, MEDLINE) and contacted the manufacturer for relevant trials up to August 2015.
  • Included randomized controlled add-on trials of stiripentol in patients with focal refractory epilepsy.
  • Extracted data on seizure frequency reduction, seizure freedom, adverse events, and treatment withdrawal.

Main Results:

  • No new studies were identified; only one study from the previous review was included.
  • The included study showed no clear evidence of stiripentol reducing seizure frequency (≥50% reduction) or achieving seizure freedom compared to placebo.
  • Stiripentol was associated with a significantly higher risk of overall adverse effects, though specific event risks had wide confidence intervals.

Conclusions:

  • No new studies were found, and the conclusions remain unchanged from the initial review.
  • There is insufficient evidence to support the use of stiripentol as an add-on treatment for focal refractory epilepsy.
  • Further large-scale, randomized, and well-conducted clinical trials are necessary to determine stiripentol's efficacy and safety.